21 completed, 9 unknown, 7 terminated, 2 recruiting. 13 Phase 2, 12 Not applicable, 8 Phase 3, 6 Phase 1, 6 Phase 4.
Follow VSL#3: new trials by email Literature Review of VSL#3 trials Research Report on VSL#3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis VSL#3, Placebo, Vedolizumab - Ulcerative Colitis | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2024-09-21 | 2024-09-24 |
| Probiotics for the Prevention of Immunotherapy Induced Colitis in Patients Receiving Immunotherapy Biospecimen Collection, Live Freeze-Dried Lactic Acid Bacteria Probiotic, Questionnaire Administration - Malignant Solid Neoplasm | Not applicable | Suspended | Mayo Clinic | 12 | 2024-07-31 | 2026-01-21 |
| Maternal Probiotic Intervention to Improve Gut Health Vivomixx, CapScan® - Environmental Enteric Dysfunction, Stunting | Phase 2 | Completed | Aga Khan University | 76 | 2023-08-09 | 2025-07-16 |
| Intervention on New Onset-T1D Children Probiotic Vivomixx®, Placebo - Type 1 Diabetes | Not applicable | Recruiting | IRCCS San Raffaele | 60 | 2022-12-16 | 2024-12-02 |
| Ability of the Probiotic Vivomixx to Improve Environmental Enteropathy in Pregnant Women: a Proof of Concept Trial in Bangladesh, Pakistan, Senegal and Zambia VSL#3, Capscan device, Placebo - Environmental Enteropathy | Phase 2 | Unknown | Tropical Gastroenterology & Nutrition Group (TROPGAN) | 76 | 2022-12-01 | 2022-11-08 |
| Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia VSL#3 - Dysphagia | Early Phase 1 | Completed | University of Wisconsin, Madison | 9 | 2018-08-27 | 2024-05-16 |
| Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia VSL#3, Placebo - Fibromyalgia, Gastrointestinal Disease | Not applicable | Completed | Elena Pita Calandre | 110 | 2018-05-11 | 2021-08-02 |
| Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics VSL#3 - Type1diabetes, Type1 Diabetes Mellitus | Not applicable | Completed | Medical College of Wisconsin | 30 | 2018-04-23 | 2024-07-22 |
| Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women VSL#3, Placebo - Menopausal Osteoporosis | Phase 2 | Terminated | Emory University | 35 | 2017-10-01 | 2020-03-04 |
| Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) VSL#3, Placebo - Juvenile Idiopathic Arthritis | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 51 | 2017-09-04 | 2026-04-06 |
| Probiotics and the Gut Microbiome in Obese Hispanic Youth VSL#3, Placebo - Obesity, Abdominal, Adiposity | Not applicable | Terminated | University of Southern California | 22 | 2015-05-30 | 2017-04-14 |
| Probiotic (Visbiome) for Gulf War Illness Placebo, Visbiome, VSL#3 - Gulf War Illness | Phase 2 / Phase 3 | Unknown | Ashok Tuteja | 60 | 2013-09-13 | 2017-12-13 |
| Probiotic (VSL #3) for Gulf War Illness VSL#3, Placebo - Gulf War Illness | Phase 2 / Phase 3 | Terminated | University of Utah | 29 | 2013-09-01 | 2018-10-26 |
| Investigating the Effect of Dietary Supplement VSL#3 on Cognition and Mood in Healthy Older Adults VSL#3, placebo - Alteration of Cognitive Function, Disturbance in Affect (Finding) | Not applicable | Unknown | University of Dublin, Trinity College | 80 | 2013-05-01 | 2015-05-27 |
| Evaluation of the Metabolome in Diverticular Disease VSL#3, Rifaximin, Mesalazine - Simple Diverticular Disease | Unknown | S.Eugenio Hospital | 40 | 2012-12-01 | 2014-10-17 | |
| A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease VSL#3 - Crohn's Disease | Phase 4 | Unknown | Federico II University | 30 | 2012-09-01 | 2014-08-12 |
| Effects of VSL#3 on Metabolic, Endocrine, Lipidomic and Inflammatory Parameters of Pediatric Patients With BMI>90° VSL#3 active probiotic, VSL#3 placebo - Obesity | Not applicable | Completed | Bambino Gesù Hospital and Research Institute | 48 | 2012-08-01 | 2017-01-31 |
| Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D VSL#3 - Irritable Bowel Syndrome | Phase 4 | Unknown | Asian Institute of Gastroenterology, India | 40 | 2012-08-01 | 2012-07-11 |
| VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer VSL#3, Placebo - Rectal Cancer | Phase 3 | Unknown | Catholic University of the Sacred Heart | 160 | 2012-03-01 | 2012-04-18 |
| Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System VSL#3, Placebo - the Local Renin-angiotensin System (RAS) in Small Intestinal Mucosa in Man | Early Phase 1 | Completed | Göteborg University | 24 | 2011-12-01 | 2021-10-15 |
Showing 20 of 40. Sign in to see all of them.
Irritable Bowel Syndrome (7) · Crohn Disease (4) · Diarrhea (4) · Colitis, Ulcerative (2) · Hepatic Encephalopathy (2) · Obesity (2) · Abdominal Pain (1) · Arthritis, Juvenile (1) · Asthma (1) · Constipation (1) · Deglutition Disorders (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · End Stage Liver Disease (1) · Enterocolitis (1)
CD Pharma India Pvt. Ltd. (2) · University of Wisconsin, Madison (2) · VSL Pharmaceuticals (2) · Aga Khan University (1) · Ashok Tuteja (1) · Asian Institute of Gastroenterology, India (1) · Assistance Publique - Hôpitaux de Paris (1) · Bambino Gesù Hospital and Research Institute (1) · Baylor College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · Catholic University of the Sacred Heart (1) · Children's Mercy Hospital Kansas City (1) · Chinese University of Hong Kong (1) · Dayton Children's Hospital (1) · Elena Pita Calandre (1)
United States (15) · Italy (7) · India (3) · Pakistan (2) · Australia (1) · Bangladesh (1) · Canada (1) · China (1) · France (1) · Hong Kong (1) · Ireland (1) · Israel (1) · Senegal (1) · Singapore (1) · South Korea (1)
Alessio Fasano, M. D. (1) · Anthony Lembo, MD (1) · Asad Ali, Dr (1) · Asad Ali, MPH (1) · Ashok Tuteja, MD, MPH (1) · Brian Lawlor (1) · Claudio De Simone, Prof. (1) · Daniel H Teitelbaum, MD (1) · Dr. Nageshwar Reddy, DM (1) · Dr. Nitesh Pratap, DM (1) · Elena P. Calandre, M.D. (1) · Erasmo Miele, Assistant Professor (1) · Fyezah Jehan, Dr (1) · Gianmarco Giorgetti (1) · Hilla Zahroni, MA (1)
PMID 24738701, PMID 16051399, PMID 16973917, PMID 21369670, PMID 21812894, PMID 21826100, PMID 23078375, PMID 23331802, PMID 23396737, PMID 23618760, PMID 23990830, PMID 24138544, PMID 24795503, PMID 24829682, PMID 24936764, PMID 25450083, PMID 26779542, PMID 27187907, PMID 31325468, PMID 32987448, PMID 34712928, PMID 35295488
R01NR005337 (1), R21AT001305 (1), R21AT003400 (1), R21AT004089 (1)